Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared ...

Cancer isn’t just one disease, but many — each with its own challenges, characteristics, risks and treatments. As we have worked tirelessly to understand this group of diseases, I’ve witnessed a ...

RBC Capital keeps an Outperform rating and $161 price target on Sarepta (SRPT), noting that while the news of an Elevidys patient death is ...

An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors (TKIs) such as lenvatinib/everolimus by highlighting key safety distinctions, ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

The addition of concurrent cisplatin chemotherapy to adjuvant radiation therapy (CRT), versus RT alone, couldn't move the ...

A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with ...

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...